Extending from evidence that aggressive gliomas express high levels of TGF-β2 believed to contribute to disease progression, the above phase IIb study was conducted to compare the safety and effectiveness of Trabedersen delivered directly into tumors with standard chemotherapy in patients with recurrent/refractory high-grade glioma [450]. This evidence concerns the gene TGFB2 and central nervous system cancer.